Market Intelligence, Clinical Progress, and High-Purity Reagents for SUMOylation Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for UBA2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UBA2 (SAE2) Wild-Type & Active Site Mutant Recombinant Protein; SAE1 partner available for heterodimer reconstitution. High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified. | View UBA2 Products |
| Gene Delivery | UBA2 Promise-ORF / Lentivirus. Full-length ORF for stable cell line engineering and target engagement assays. | View UBA2 Products |
| Detection Antibody | Anti-UBA2 Recombinant Antibody (monoclonal). Sequence-defined binder for SPR, WB, IHC, and immunofluorescence. | View UBA2 Products |
| Validator | UBA2 siRNA Set. For knockdown-mediated specificity verification in cellular assays and synthetic lethality models. | View UBA2 Products |
| Related Target: SAE1 | SAE1 Recombinant Protein. Obligate heterodimeric partner of UBA2; essential for SUMO E1 enzymatic activity. | View SAE1 Products |
| Related Target: UBE2I (UBC9) | UBE2I Recombinant Protein. Downstream SUMO E2 conjugating enzyme for thioester transfer and cascade assays. | View UBE2I Products |
| Related Target: MYC | MYC Recombinant Protein or ORF. Oncogenic driver conferring high dependency on UBA2-mediated SUMOylation; useful for synthetic lethality models. | View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimeric activity reconstitution (UBA2 + SAE1) | Co-expressed UBA2/SAE1 heterodimer available; >95% purity; endotoxin controlled. |
| Catalytic site specificity screening | Active site Cys→Ser mutant available as rigorous enzymatic negative control; sequence verified. |
| Selectivity vs. Ubiquitin E1 pathway (UBA1) and other E1 enzymes (NAE, UAE) | Human UBA1, NAE, and UAE orthologs available for off-target counter-screening; mass spec verified. |
| Cellular target engagement & reporter lines | UBA2 lentiviral particles for stable integration into engineered cell lines. |
| False positives in compound screening | Gene-specific UBA2 siRNA for orthogonal target specificity confirmation; validated in MYC-driven models. |
| Lack of reliable pathway controls | Benchmark antibodies included for standardized cellular target engagement readouts (Western blot, IHC). |
Live UBA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for UBA2-targeted therapeutics is intensifying, with the field shifting from broad cytotoxics toward precise modulation of protein homeostasis. Clinical development has been spearheaded by Takeda with TAK-981 (subasumstat), a molecule that inhibits the UBA2/SAE1 SUMO E1 heterodimer by forming a covalent adduct with SUMO. This approach has established critical proof-of-concept in MYC-driven hematologic malignancies and selected solid tumors. UBA2 is highly upregulated in various malignancies. As first-generation inhibitors advance, the next wave of R&D is targeting next-generation allosteric inhibitors, reversible chemotypes, and combination regimens with BCL-2 or CDK inhibitors to exploit synthetic lethality. Additionally, combining UBA2 inhibitors with immuno-oncology agents leverages SUMO-inhibition-induced innate immune activation (Type I interferon signaling).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Covalent) | Takeda (TAK-981 / Subasumstat) | Hematologic Malignancies, Solid Tumors, Lymphoma | E1-E2 Thioester Assay; need high-purity active UBA2/SAE1 heterodimer |
| Small Molecule (Allosteric / Reversible) | Early-stage Biotech, Academic Labs | MYC-driven Cancers | Heterodimer Disruption / SPR; need full-length WT & mutant proteins; homolog E1 proteins for selectivity |
| Targeted Protein Degradation (PROTAC) | Emerging Discovery Platforms, Academic/Emerging Pharma | Refractory Cancers | Cellular reporter lines; need UBA2 lentivirus for stable integration; validated UBA2 antibodies for degradation readouts |
Future Directions & Assay Strategy
Upcoming Trends
- Immuno-oncology combinations: UBA2 inhibitors combined with anti-PD-1/PD-L1 checkpoint inhibitors are expected to be a major clinical trend due to innate immune activation upon SUMO inhibition.
- Resistance mutations: Long-term use of covalent inhibitors may lead to mutations in the catalytic domain (e.g., Cys173); second-generation inhibitors (reversible, allosteric) or PROTACs will be needed.
- Selectivity challenges: Inhibitors must achieve high selectivity for UBA2 over other E1 enzymes (UBA1, NAE, UAE) to avoid pleiotropic toxicity.
Recommended Assays
- Enzymatic reconstitution assay: TR-FRET or fluorescence polarization measuring SUMO transfer from UBA2/SAE1 to UBC9.
- Cross-reactivity panel: SPR or MS parallel testing against UBA2, NAE, UAE, UBA1.
- Adduct monitoring (for covalent inhibitors): Mass spectrometry to confirm stoichiometry of inhibitor binding to active-site cysteine.
TarMart Solutions
- Co-expressed SAE1/UBA2 heterodimer protein (E. coli or baculovirus) with >95% purity, low endotoxin (<1 EU/µg).
- Lentiviral particles carrying wild-type and mutant UBA2 for stable cell line generation.
- Full panel of related target proteins (SAE1, UBE2I, MYC, UBA1, NAE, UAE) for comprehensive selectivity screening.